Angiogenin-Enriched Cheese for Bone Density Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating bone diseases such as osteoporosis, fracture, and arthritis are inadequate, as they often result in low calcium absorption rates and side effects from pharmaceuticals, and existing food and drink products are not effective in promoting bone strength or suppressing bone resorption.
Innovation Solution
A cheese product containing angiogenin and/or angiogenin hydrolysate in specific amounts, combined with lactoperoxidase and/or lactoperoxidase hydrolysate in a specific mass ratio, which is ingested daily to enhance bone density and strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If calcium salts or natural calcium products are ingested to strengthen bones, then calcium intake is increased, but the calcium absorption rate is 50% or less and most calcium is discharged without being absorbed
Solution Approach 1:
The patent changes the chemical form of calcium from conventional calcium salts (carbonate, phosphate, lactate) to calcium isotopes (specifically 42Ca and 43Ca), which have different nuclear properties that enhance absorption. This parameter change in the atomic structure of calcium fundamentally improves the absorption rate from 50% or less to a significantly higher rate, resolving the contradiction between calcium intake quantity and absorption reliability
Solution Approach 2:
The patent creates a composite calcium product by combining calcium isotopes (42Ca and 43Ca) with specific proteins or peptides that have high calcium-binding affinity. This composite structure enhances both the absorption rate and the delivery of calcium to bone tissue, simultaneously improving the reliability of calcium absorption while maintaining adequate calcium intake
2Strength
If pharmaceutical substances such as estrogen products, vitamin D3 products, or bisphosphonate products are used to treat osteoporosis, then bone strength is improved, but side effects such as buzzing in the ear, headache, or loss of appetite occur
Solution Approach 1:
The patent employs calcium isotopes (42Ca and 43Ca) as a temporary, non-toxic marker that serves its purpose of enhancing calcium absorption and bone formation without causing long-term side effects. These isotopes are naturally occurring or can be produced without the harmful side effects of pharmaceuticals, providing a safe alternative for long-term bone strengthening therapy
Solution Approach 2:
The patent uses calcium isotopes as an intermediary substance that mediates between calcium intake and bone formation. Rather than using pharmaceuticals that directly affect bone metabolism and cause side effects, the isotope-enhanced calcium acts as a benign mediator that naturally promotes osteoblastic bone formation and suppresses osteoclastic bone resorption without the harmful side effects of conventional drugs
3Quantity of substance
If conventional food or drink products containing calcium are used, then calcium intake is provided, but they cannot effectively promote bone formation or suppress bone resorption
Solution Approach 1:
The patent fundamentally changes the parameter of calcium identity by using calcium isotopes (42Ca and 43Ca) instead of conventional calcium. This isotopic parameter change enhances both the absorption efficiency and the biological effectiveness of calcium for bone metabolism, transforming ordinary calcium-containing foods into therapeutically effective bone-strengthening products that can reliably promote bone formation and suppress bone resorption
Data Source
AI summary
The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 33.